Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 2066509 approvals12 trials

EuBiologics Co., Ltd.

Official website

KOSDAQ-listed vaccine maker supplying oral cholera vaccine to UNICEF alongside a biologics CRMO business.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2010 and listed on KOSDAQ in 2017, EuBiologics specializes in vaccine development and supply as well as biologics CRMO (contract research and manufacturing) services. It supplies oral cholera vaccine to UNICEF and is pursuing follow-on vaccines such as typhoid and meningococcal vaccines, along with premium vaccines targeting developed markets. Its 2025 cholera vaccine revenue reached KRW 145.2 billion, growing more than 30% annually, while its CRMO business maintains annual revenue of KRW 3-6 billion.

Products & technology

  • Oral cholera vaccineCholera prevention vaccine supplied to UNICEF
  • CRMO (Contract Research and Manufacturing Organization) servicesContract research and manufacturing for biologics

Regulatory approvals

data.go.kr

5 Korean MFDS drug approvals · 2015–2025 / 4 Korean MFDS device approvals · 2020–2021

  • MFDS drugEuTYPH-C Inj. Multi-dose(Typhoid Purified Vi Polysaccharide Conjugated to Diphtheria CRM197 Vaccine)2025-07-30
    Drug · Prescription · Approval202501995
  • MFDS drugEuvichol-S2023-12-19
    Drug · Prescription · Approval202303370
  • MFDS drugEuCorVac-19 Inj. Multi-dose(SARS-CoV-2 Spike Protein Vaccine(Recombinant))2023-01-30
    Drug · Prescription · Approval202300374
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2021-01-28
    Product approval · Class 3체외 제허 21-72 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2020-11-19
    Product approval · Class 3체외 제허 20-980 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-09-17
    Product approval · Class 3체외 제허 20-818 호
  • MFDSBandage, compressionRevoked2020-05-26
    Product approval · Class 1제신 20-718 호
  • MFDS drugEuvichol-Plus2017-03-29
    Drug · Prescription · Approval201701512
  • MFDS drugEuvichol2015-01-28
    Drug · Prescription · Approval201500462

Clinical trials

data.go.kr

12 MFDS clinical trial authorisations · 2012–2025 (Phase 1 8 · Phase 1/2 3 · Phase 3 1)

  • Phase 1mCOV백신(사스코로나바이러스-2 mRNA 백신)2025-12-23
  • Phase 1EuHZV(유바이오로직스 대상포진 백신)2024-04-19

    1 trial site

  • Phase 1호흡기세포융합바이러스 백신(RSV vaccine)2024-01-02

    1 trial site

  • Phase 1/2유코백-19(EuCorVac-19)2022-12-06

    1 trial site

  • Phase 1EuCCV주/EuCCV-AL주2022-04-15

    3 trial sites

  • Phase 3유코백-19(EuCorVac-19)2022-01-28

    1 trial site

  • Phase 1/2유코백-19(EuCorVac-19)2021-01-20

    5 trial sites

  • Phase 1EuMCV5주2021-01-06

    1 trial site

  • Phase 1EuMCV4주2020-06-11

    1 trial site

  • Phase 1EuPCV15주 (폐렴구균-디프테리아 CRM197단백 접합 백신)2019-10-01

    1 trial site

  • Phase 1/2ATGC-100주2019-03-19

    1 trial site

  • Phase 1유비콜2012-07-31

    1 trial site

R&D and key agreements

Source: DART corporate disclosure

장티푸스 백신 · 장티푸스 · 개발중 · Follow-on vaccine pipeline after cholera vaccine

수막구균 백신 · 수막구균 감염증 · 개발중

프리미엄 백신 · 개발중 · Premium vaccine targeting developed markets

Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

CALTH. Inc2 shared

Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.

GC Medical Science Corporation2 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

Gencurix Inc.2 shared

Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.

HUMASIS CO., LTD.2 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

iNtRON Biotechnology, Inc.2 shared

Founded in 1999 and listed on KOSDAQ in 2011, iNtRON Biotechnology develops bacteriophage-based new drugs via its itLysin and IMPA platforms alongside a molecular diagnostics business.

NanoenTek,Inc.2 shared

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

OSANG HEALTHCARE CO.,LTD.2 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

PharmGen Science, Inc.2 shared

Founded in 1966, KOSPI-listed PharmGen Science makes GI and cardiovascular prescription drugs plus health foods and beauty products.

PROTIA INC.2 shared

KOSDAQ-listed in-vitro diagnostics company selling PROTIA Allergy-Q allergy diagnostic products domestically and in 80+ countries.

SD BIOSENSOR INC.2 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

SLSBio(Specialty Lab Solution Bio) Co., Ltd2 shared

Founded 2007, KOSDAQ-listed 2023, SLSBio provides pharmaceutical quality control, drug development support, and in vitro diagnostics.

Sugentech, Inc.2 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition